HelloFresh and No Kid Hungry Launch Hunger Hero Campaign to Combat Summer Hunger
NEW YORK--(BUSINESS WIRE)--HelloFresh, the world's leading meal kit provider, and No Kid Hungry, a campaign focused on ending childhood hunger, announced today the 'Hunger Hero' campaign to raise awareness of rising hunger across the US. The meal kit brand is tapping celebrated online chefs and dedicated hunger relief advocates, including Tini Younger, Eitan Bernath and Becca and Justin Schwartz, to serve as ambassadors of the campaign and raise awareness of childhood food insecurity during the summer months, inspiring others to join in the cause.
In the US, 1 in 5 kids face hunger. This staggering reality is only heightened during the summer months.
Share
In the US, 1 in 5 kids face hunger. This staggering reality is only heightened during the summer months when kids are out of school and lose access to the dependable nutrition they get at school during the academic year. Impending cuts to SNAP and other critical programs, coupled with a looming crisis for food banks, threaten to make the issue even worse.
Galvanizing Hunger Heroes to Help Fight Food Insecurity
Through a combination of social- and event-led initiatives, the Hunger Hero campaign will provide individuals with a call-to-action to help address childhood hunger in their own communities.
HelloFresh kicks off the program today with a series of distribution events in New York City, NY; Atlanta, GA; and Phoenix, AZ where families can access free HelloFresh meal kits filled with nutritious, family-friendly recipes, along with vital resources on summer EBT, SNAP benefits and information on where to access support through No Kid Hungry. Each event will be joined by a notable 'Hunger Hero,' an influencer, chef, and or 'foodie' who is actively committed to fighting food insecurity in their own communities. Tini Younger, who volunteers in her own backyard at Atlanta Mission, Eitan Bernath, a high-level supporter of the United Nations World Food Programme; and Becca and Justin Schwartz, who actively volunteer with Feed My Starving Children by hosting community volunteer events with their followers, will all serve as Hunger Heroes, providing assistance and awareness about the issue.
Beyond hosting these events, each Hunger Hero will call upon their followers to commit to fighting hunger — whether through donating to No Kid Hungry, volunteering at a local food bank or even simply raising awareness in their own communities. For every like, share, or comment on campaign-related posts, HelloFresh will make a donation to No Kid Hungry in support of their vital work feeding families year-round up to $10,000 from June through August.
The meal kit brand will also be running a social media campaign spotlighting everyday hunger heroes — including food bank leaders and educators — to spotlight the important work they do every day and inspire the brand's followers to join in the cause.
'From my time volunteering at Atlanta Mission, I've met many families trying their best, but struggling to put meals on the table,' said viral chef Tini Younger. 'Fighting food insecurity is deeply important to me. Being a part of this campaign is not just about food. It's about dignity, joy and the chance for kids to be kids.'
'Every day, we're witnessing more families struggling with hunger — and during the summer months, the need becomes even more urgent,' said Adam Kalikow, Senior Vice President and Managing Director at HelloFresh US. 'That's why we're doubling down on our efforts to help close the summer hunger gap. By partnering with some notable 'hunger heroes' like Tini, Eitan, Becca and Justin, we're able to bring more attention to this growing issue while making a tangible impact. We invite everyone to get involved and look forward to spotlighting hunger heroes across the country — those stepping up and making a real difference in their communities.'
'We're incredibly thankful for the continued support from HelloFresh to combat childhood food insecurity,' said Allison Shuffield, Managing Director of Corporate Partnerships. 'At a time of increased need, the support from corporations like HelloFresh is that much more important to ensure children are not going hungry this summer.'
To learn more about how HelloFresh and No Kid Hungry are fighting childhood food insecurity and to join the Hunger Hero movement in the action, please visit hellofresh.com/pages/nokidhungry or @HelloFresh on social media.
ABOUT HELLOFRESH
HelloFresh is the world's leading meal-kit company, providing customers with fresh, high-quality ingredients to cook delicious meals at home. By delivering pre-portioned ingredients and easy-to-follow recipes directly to customers' doors, HelloFresh helps busy individuals and families enjoy home-cooked meals without the hassle of meal planning and grocery shopping. HelloFresh was voted the Most Trusted Meal Kit Delivery Service in America from 2021 through 2023 by Newsweek. For more information, visit www.hellofresh.com or follow HelloFresh on Facebook, X, Instagram, or TikTok.
ABOUT HELLOFRESH GROUP
The HelloFresh Group is a global food solutions group and the world's leading meal kit provider. The HelloFresh Group consists of eight brands that provide customers with high quality food and recipes for different meal occasions including HelloFresh, Green Chef, EveryPlate, Chefs Plate, Factor, Youfoodz, The Pets Table and Good Chop. The Company was founded in Berlin in November 2011 and operates in the USA, the UK, Germany, the Netherlands, Belgium, Luxembourg, Australia, Austria, Switzerland, Canada, New Zealand, Sweden, France, Denmark, Norway, Italy, Ireland and Spain. In Q1 2024 HelloFresh Group delivered over 272 million meals globally. HelloFresh SE went public on the Frankfurt Stock Exchange in November 2017 and is currently traded on the MDAX (Mid-Cap German Stock Market Index). For more information, visit www.hellofreshgroup.com.
ABOUT NO KID HUNGRY
No child should go hungry in America. But millions of kids in the United States live with hunger. No Kid Hungry is working to end childhood hunger by helping launch and improve programs that give all kids the healthy food they need to thrive. This is a problem we know how to solve. No Kid Hungry is a campaign of Share Our Strength, an organization committed to ending hunger and poverty.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 hours ago
- The Hill
Booker calls Trump megabill a ‘moral obscenity'
Sen. Cory Booker (D-N.J.) said Monday that President Trump's 'big, beautiful bill' is a 'moral obscenity.' 'I think it's a moral obscenity, and it is violence in the sense of what it will do to many families by denying them health care when they're sick, by denying them food when their children are hungry, denying our seniors critical care in their latter years, denying the disabled the kind of support that they need,' Booker said on MSNBC's 'Deadline: White House.' Democrats have vehemently opposed the 'big, beautiful bill' as it has made its way through Congress, with Booker saying in a post on the social platform X Monday that members of his party in the upper chamber were 'standing up right now for our constituents who will lose their health care, who will face rising energy costs, and who will lose access to SNAP benefits.' 'We have to do whatever we can to stop the 'Big Beautiful Bill,' Booker continued in his post. House moderate Republicans and hard-line conservatives have recently expressed rising opposition to the Senate's version of the 'big, beautiful bill' only days before they are set to consider the legislation. 'This bill is a moral obscenity, and I'm stunned that only a few senators on their side of the aisle have even been willing to speak to the impact it will have on their states, their constituents,' Booker said Monday. In a post on Truth Social, Trump said Monday that the 'ONE GREAT BIG BEAUTIFUL BILL, is moving along nicely!' 'MAKE AMERICA GREAT AGAIN!' the president added, using his trademark phrase.
3 hours ago
Meet some people who would feel the effects of Trump's 'big, beautiful bill'
As Republicans in the House and Senate sprint to pass President Donald Trump's signature One Big Beautiful Bill Act, we found Americans in their own scramble, poring over the bill's hundreds of pages and trying to determine how their lives might change. Here's a little of what they told us: SNAP and Medicaid cuts To try to pay for the bill's trillions of dollars in tax cuts, congressional Republicans are cutting or changing the funding mechanisms for programs like Medicaid and the Supplemental Nutrition Assistance Program (SNAP), the vital food assistance initiative. Tanja, who asked that we not use her last name, is on both. Sitting in her wheelchair next to her loyal service dog Zoe, she told ABC News she's never followed a bill this closely. She's living paycheck-to-paycheck and can't afford the specific foods her doctors say she needs without SNAP. Tanja: There is not a lot left over in my monthly allowance for anything. Tanja: Yeah, even… O'Brien: Even worse? Tanja: Even worse. Worse than that. 'The way it's going right now, and it's not just me, we're all scared,' she added. The Senate version of the megabill cuts agriculture programs by roughly $186 billion, most of which will come out of SNAP. And, health care providers are concerned, too. Ruben Bastell is a lab technician at a New York hospital, where he says roughly four in 10 patients are on Medicaid, the health insurance program for low-income Americans and those with disabilities. The current version of the budget bill imposes new work requirements on Medicaid recipients and increases the required paperwork to verify eligibility. It would also start to cut what's known as the provider tax, which helps fund state obligations to Medicaid, in 2028 Both could result in millions less on the program and, Bastell warns, could upend parts of the U.S. health care system. Bastell: Eventually hospitals are going to have to close their doors . O'Brien: What is that going to do to patient care in general? Bastell: Patient care? It's definitely going to delay it. A lot of patients won't be able to get treated. Republicans say those concerns are overblown and they are making both Medicaid and SNAP more sustainable by targeting waste, fraud and abuse in both programs. The bill's changes to Medicaid are expected to cause 11.8 million Americans to lose their insurance, according to a recent analysis by the nonpartisan Congressional Budget Office. Slashing green energy tax incentives In addition to cuts in programs like Medicaid and SNAP to help pay for the bill, the legislation phases out Biden-era green energy tax incentives, particularly for wind and solar power. Micah Gold Markel is deeply nervous about that. His small Philadelphia company Solar States has swelled in the last few years, thanks to increased demand because of those tax incentives. Now, he's worried he may need to fire half of his employees if those credits are rolled back. Many of his employees voted for Trump, he says, in the must-win state of Pennsylvania. And now their jobs could be on the line because of his bill. Markel: The hardest part of being a business owner is laying people off. Hands down, hands down… O'Brien: Are you worried you're going to have to do that more? Markel: (tears up) I'm really worried about that, yeah. Markel has been driving back and forth from his warehouse to Capitol Hill, lobbying against slashing the green energy incentives. And while the Senate has lessened how quickly some of the tax credits will get phased out, he and the others in his industry have largely been unsuccessful. 'I think some [lawmakers] think that the jobs are not real. And I don't know, other than to come in front of them and to tell them I was born in West Philly. This is my job. I don't know what else to say to them, and some of them still look you in the face, and they just don't believe you,' he said. Taxes and Trump accounts In Englewood, New Jersey, we met firefighters who, between juggling 911 calls, are also watching Congress closely. But they're excited. Trump's bill includes a key campaign promise: no federal income taxes on tips and overtime. And while some service workers have celebrated the tips portion, the firefighters we met are focused on their OT. They work a lot of it. 'It could be in the thousands of dollars that a firefighter could get. More of a refund when they do the taxes, for sure,' said Matt Caliente, a former firefighter and president of the Professional Firefighters Association of New Jersey. The union's national arm has endorsed the overtime provision of the bill. 'It certainly lightens the burden for your family. Pays for things like childcare and some rest, some vacations,' Ed Zebrowski, a Cape May, New Jersey, firefighter added. Another section causing some excitement -- so-called 'Trump accounts' -- investment accounts for newborns -- would open with a one-time deposit from the federal government of $1,000. '[These] initiatives are going to Main Street and America and helping everyday people succeed,' Uber CEO Dara Khosrowshahi said recently at a White House event. The bill also includes a roughly $4 trillion tax cut, largely by making Trump's 2017 tax law permanent before it was due to expire. Because the law is currently on the books, most Americans largely won't see a change to their yearly tax filings because of this bill, but they also won't pay more. Blocking AI regulation Another provision buried in the bill -- which came as a surprise to some House Republicans who say they didn't read it before voting on it -- is a ban on any state or local regulations on artificial intelligence for 10 years. The move would block laws on the books in more than 20 states, including those covering AI scams, election misinformation and explicit deepfake images of children. Marty Jackley, South Dakota's attorney general, said the state's Legislature worked hard to pass its bans on AI-generated misinformation and deepfakes and he's calling on fellow Republicans in Congress to change course. 'All it does is prevent the states that already have laws in place from protecting our citizens against AI-generated child porn, against election manipulation and consumer fraud,' he said.
Business Wire
5 hours ago
- Business Wire
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced details of Embolden™, the Company's registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older. The Company has written agreement from the U.S. Food and Drug Administration (FDA) on key aspects of the registrational trial's design. 'We appreciate the partnership with the FDA as we aligned on the key elements of our NGN-401 registrational trial design, which will allow for rapid conversion of the current Phase 1/2 study to a pivotal trial,' said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We believe that the robust endpoint design, which was informed by key opinion leaders, caregiver input and primary market research with payors, will support NGN-401's best-in-class potential and provide key differentiating data critical to the Rett syndrome community and the future commercial success of NGN-401.' 'I appreciate the multi-domain approach across the clinical manifestations of Rett syndrome, and rigor in which the primary endpoint will be evaluated, including both the clinician perspective of improvement using the CGI-I scale with Rett syndrome anchors and videos to demonstrate gains of skills that are clinically meaningful for girls and women with Rett syndrome and their families,' said Elizabeth M. Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University, and principal investigator in the NGN-401 clinical trial. 'Participants treated with NGN-401 have demonstrated increased independence, with both fine and gross motor function improvement, and gained the ability to better communicate wants, needs and choices. I have been impressed with the improvements observed in participants after NGN-401 administration, which have included global improvement in signs and symptoms of Rett syndrome and gains of multi-domain developmental milestones that would not be expected to occur spontaneously in the post-regression stage of Rett syndrome. Evaluating treatment effect in participants ages 3 and above in the registrational study will provide important insights on the potential benefits of NGN-401 in younger patients early in the course of this progressive disease.' Obtained Written Agreement from FDA on the Following Key Elements of Embolden Registrational Trial Design After Discussions Under the START Program Study Design: Open-label, single arm, baseline control (i.e., participants serving as their own control); N=18 proposed, subject to feedback from the FDA. Patient Population: Females ages ≥ 3 years with Rett syndrome, which is consistent with Neurogene's analysis of the NIH-sponsored, International Rett Syndrome Foundation (IRSF) Rett syndrome natural history study that shows patients ages 3 and above rarely learn new skills/reach developmental milestones or relearn skills once lost. The FDA's written agreement endorsed the Company's analysis. Dose: 1E15 vector genomes (vg). Primary Endpoint: Responder-based composite endpoint that will assess an improvement in the Clinical Global Impression-Improvement (CGI-I) scale with Rett syndrome anchors and the gain of a developmental milestone/skill, compared to a participant's own baseline. Responders are defined as participants who: Attain a CGI-I score of ≤ 3 ('minimally improved'); and Gain any one developmental milestone/skill from a list of 28, as captured through standardized video recordings and independently verified by blinded central raters. Developmental milestones/skills were informed by a Rett syndrome caregiver survey, provided to the FDA, demonstrating that the acquisition of any single skill within the selected set is considered clinically meaningful. The primary endpoint will be evaluated at 12 months following NGN-401 administration, with feedback pending from the FDA to consider the addition of a 6-month endpoint. Neurogene has begun registrational trial initiation activities. 'It has been incredibly rewarding to see how RSRT's early investments in foundational Rett syndrome science helped lay the groundwork for what's now a promising gene therapy program approaching a registrational trial,' said Monica Coenraads, Founder and Chief Executive Officer of RSRT. 'RSRT has been a long-time champion of addressing the underlying genetic cause of Rett syndrome and Neurogene's program has the potential to do just that. We appreciate the thoughtful design of the trial that importantly incorporates the caregiver perspective on what meaningful improvement may look like. We congratulate the Neurogene team on reaching alignment with the FDA and thank the Rett community at large for their support in advancing this program. The future is bright!' 'Our partnership with Neurogene reflects a shared commitment to accelerating meaningful treatments for Rett syndrome,' said Laura Hameed, Chief Executive Officer of the International Rett Syndrome Foundation (IRSF). 'The use of IRSF's Natural History Study data to support the NGN-401 gene therapy registrational trial design is a powerful example of how families accelerate and streamline therapeutic development. We are grateful to the families that contributed to the NHS, and to the families participating in this trial whose time and commitment are essential to evaluating gene therapy for Rett syndrome.' Phase 1/2 Trial Data Support Registrational Trial Design Previously disclosed clinical data from the Phase 1/2 study* support the registrational trial design. Data showed improvements in Rett syndrome assessments with an aggregate of 23 developmental milestones/skills acquired in the first four participants. Specifically, the four participants: Each achieved a clinically meaningful rating of 2, or 'much improved,' on the CGI-I; and Collectively achieved 23 developmental milestones/skills in the core clinical domains of Rett syndrome – hand function/fine motor, communication/language, and ambulation/gross motor, including: Participant 1 gained 10 skills across multiple domains by 15 months post-dose; Participant 2 gained 8 skills across multiple domains by 12 months post-dose; Participant 3 gained 3 skills across multiple domains by 9 months post-dose; and Participant 4 gained 2 skills by 3 months post-dose. *Efficacy data from the first four participants; as of data cut-off date of October 17, 2024 Phase 1/2 Trial Enrollment and Update Neurogene previously shared that five additional participants had been dosed in the Phase 1/2 portion of the NGN-401 clinical trial during the first half of 2025. A total of 10 participants have received the 1E15 vg dose. There has been no evidence of hemophagocytic lymphohistiocytosis (HLH) / hyperinflammatory syndrome in any participant at the 1E15 vg dose level. Neurogene remains on track to share updated clinical efficacy and safety data in the second half of 2025. Cash Runway Update As of March 31, 2025, Neurogene had cash, cash equivalents, and investments of $292.6 million. The Company's current budget reflects a reallocation of capital from pipeline development to support pivotal trial activities for NGN-401. Neurogene now expects its existing resources will be sufficient to fund operations into early 2028. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial and the addition of a six month endpoint, and timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial; expected future interactions with or positions of the FDA; the safety, tolerability and efficacy of NGN-401; the potential for success of the Embolden registrational clinical trial for NGN-401 for the treatment of Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome; the effectiveness of the monitoring and treatment protocol for HLH in Neurogene's Phase 1/2 clinical trial of NGN-401; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things, uncertainties regarding interactions with and feedback received from the FDA staff responsible for approving the design of our registrational trial and the risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 24, 2025, Neurogene's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 9, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
